Lead Peptide Program

About ResoTher Pharma

ResoTher Pharma is a private, clinical-stage biotech developing a novel class of peptide therapeutics designed as resolution therapy for inflammatory-driven cardiovascular diseases. The company's lead program is in Phase 2a for myocardial infarction, targeting neutrophil-driven inflammation to terminate the inflammatory response and promote tissue regeneration. ResoTher operates in the high-unmet-need space of acute cardiovascular interventions, leveraging recent clinical discoveries that pinpoint inflammation as a key prognostic determinant. Its strategy is to provide additional therapeutic benefit where current standard of care falls short.

Therapeutic Areas

Other Myocardial Infarction Drugs